A reversal of brain damage caused by Alzheimer

Alzheimer; News from the web:

More news on the great trial from Biogen:

A new Alzheimer’s drug that reverses the damage the disease causes in patients’ brains could ‘change the landscape’ of future treatment, according to researchers.

It has already performed so well at early-stage trials involving people living with the disease in the United States that scientists are now in talks aimed at leapfrogging the usual second stage and fast-tracking it for larger trials.

Pharmaceutical firm Biogen, which developed the drug, called aduncanumab, wants to recruit at least 1,000 patients for tests by the end of the year.

Read all about it HERE

Great News, another drug seems to work to fight alzheimer!

Alzheimer; News from the web:

An experimental drug for Alzheimer’s disease sharply slowed the decline in mental function in a small clinical trial, researchers reported Friday, reviving hopes for an approach to therapy that until now has experienced repeated failures.

The drug, being developed by Biogen Idec, could achieve sales of billions of dollars a year if the results from the small trial are replicated in larger trials that Biogen said it hoped to begin this year. Experts say that there are no really good drugs now to treat Alzheimer’s.

Read all about it HERE

Alzheimer research with Dogs

Alzheimer; News from the web:

“Several studies have shown amazing improvements in the memory and learning of older dogs by feeding them a diet rich in antioxidants— mainly fruits and vegetables. And they’ve also seen an improvement in the learning behavior improved with plenty of exercise, mental stimulation, and lots of socialization with other dogs. So just like with humans, we can be proactive about helping our aging pets through diet and exercise.”

Read all about it HERE

New molecule identified that may delay Onset Alzheimer

Alzheimer; News from the web:

Scientists at the University of Cambridge have identified a crucial molecule that could put the brakes on the damage to the brain:

Samuel Cohen, who led the study at the University of Cambridge, said: “The big advantage is that we haven’t just come up with a drug and not really understood what it is doing. We’ve come up with a general strategy that could work.”

Read all about it HERE